spaglumic acid Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG PubChem

Active Ingredient History

NOW
  • Now
N-Acetylaspartylglutamic acid is a peptide neurotransmitter and the third-most-prevalent neurotransmitter in the mammalian nervous system. NAAG consists of N-acetylaspartic acid (NAA) and glutamic acid coupled via a peptide bond.   Wikipedia

Chemistry

  • SMILES: CC(=O)N[C@@H](CC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O
  • InChIKey: GUCKKCMJTSNWCU-BQBZGAKWSA-N
  • Mol. Mass: 304.25
  • ALogP: -1.6
  • ChEMBL Molecule:
    spaglumic acid  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

beta-naag | n-acetyl-l-β-aspartyl-l-glutamic acid | spaglumic acid

Organizations (2)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (3)

Approved Indications (1)


 

Hypersensitivity

Experimental Indications - Clinical Trial Phases 1-4 (2)


 

Conjunctivitis, Allergic (Phase 4)

Inflammation ()

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue